SIR X1
Alternative Names: SIR-X1Latest Information Update: 13 Feb 2026
At a glance
- Originator Sironax
- Class
- Mechanism of Action SARM1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 19 Jan 2026 Preclinical trials in Neurodegenerative disorders in China (unspecified route) (Sironax pipeline, January 2026)